Cross Country Healthcare, Inc. ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Cross Country Healthcare, Inc. zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Cross Country Healthcare, Inc. zu Deinem Portfolio hinzuzufügen.
BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (the Company) (Nasdaq: CCRN) today announced financial results for its third quarter ended September 30, 2025. Selected Financial Information: Variance Variance Q3 2025 vs Q3 2025 vs Dollars are in thousands, except per share amounts Q3 2025 Q3 2024 Q2 2025 Revenue $ 250,052 (21 )% (9 )% Gross profit margin* 20.4 ...
BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country announced today that its marketing team has been named the No. 1 Marketing Team in the Nation by the 2025 OnCon Icon Awards.
Cross Country Healthcare (CCRN 2.02%), a major provider of healthcare staffing solutions, reported its second quarter results on August 6, 2025. The company reported a substantial miss on both GAAP revenue and non-GAAP EPS.
BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (the Company) (Nasdaq: CCRN) today announced financial results for its second quarter ended June 30, 2025. Selected Financial Information: Variance Variance Q2 2025 vs Q2 2025 vs Dollars are in thousands, except per share amounts Q2 2025 Q2 2024 Q1 2025 Revenue $ 274,072 (19 )% (7 )% Gross profit margin* 20.4 % ...
I previously rated CCRN a sell, arguing that the FTC could block the merger because of concerns about competition in healthcare markets. The stock price now offers a 45% upside if the Aya merger closes, with the market pricing in only a 22% chance of the deal completing. Management continues to guide toward the deal completing in the second half of 2025.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.